Pasar al contenido principal

DESCIFRANDO EL PAPEL DE NOR-1 EN LA PROGRESION DEL ANEURISMA DE AORTA ABDOMINAL, LA ARRITMOGENESIS CARDIACA, Y LA FUNCION Y EL REMODELADO CARDIACO TRAS INFARTO DE MIOCARDIO

PID2021-122509OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 22
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

NADPH Oxidase 5 (NOX5) Upregulates MMP-10 Production and Cell Migration in Human Endothelial Cells

  • Marqués, J.
  • Ainzúa, E.
  • Orbe, J.
  • Martínez-Azcona, M.
  • Martínez-González, José|||0000-0002-3894-7166
  • Zalba, G.
NADPH oxidases (NOXs) have been described as critical players in vascular remodeling, a mechanism modulated by matrix metalloproteinases. In this study, we describe for the first time the upregulation of MMP-10 through the activation of NOX5 in endothelial cells. In a chronic NOX5 overexpression model in human endothelial cells, MMP-10 production was measured at different levels: extracellular secretion, gene expression (mRNA and protein levels), and promoter activity. Effects on cell migration were quantified using wound healing assays. NOX5 overexpression increased MMP-10 production, favoring cell migration. In fact, NOX5 and MMP-10 silencing prevented this promigratory effect. We showed that NOX5-mediated MMP-10 upregulation involves the redox-sensitive JNK/AP-1 signaling pathway. All these NOX5-dependent effects were enhanced by angiotensin II (Ang II). Interestingly, MMP-10 protein levels were found to be increased in the hearts of NOX5-expressing mice. In conclusion, we described that NOX5-generated ROS may modulate the MMP-10 expression in endothelial cells, which leads to endothelial cell migration and may play a key role in vascular remodeling.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Inhibition of ATP-citrate lyase by bempedoic acid protects against abdominal aortic aneurysm formation in mice

  • Puertas Umbert, Lídia|||0000-0002-2739-6522
  • Almendra-Pegueros, Rafael|||0000-0002-4411-4515
  • Camacho, Mercedes|||0000-0001-5970-3294
  • Rodríguez Sinovas, Antonio|||0000-0003-2930-8773
  • Galán, María|||0000-0002-4758-8388
  • Roglans, Nuria
  • Laguna, Joan Carles|||0000-0002-2357-1186
  • Martínez-González, José|||0000-0002-3894-7166
  • Rodríguez, Cristina|||0000-0002-6472-5647
  • Alonso Nieto, Judith|||0000-0003-0537-0417
  • Blanco-Casoliva, Laia
Abdominal aortic aneurysm (AAA) is a prevalent degenerative disease characterized by an exacerbated inflammation and destructive vascular remodeling. Unfortunately, effective pharmacological tools for the treatment of this disease remain a challenge. ATP-citrate lyase (ACLY), the primary enzyme responsible for acetyl-CoA biosynthesis, is a key regulator of inflammatory signaling in macrophages and lymphocytes. Here, we found increased levels of the active (phosphorylated) form of ACLY (p-ACLY) in the inflammatory infiltrate of AAA from patients and in aneurysmal lesions from angiotensin II (Ang II)-infused apolipoprotein E-deficient mice (ApoE). Furthermore, plasma ACLY levels positively correlates with IL6 and IFNγ levels in patients with AAA, while inflammatory stimuli strongly upregulated ACLY expression in macrophages and Jurkat cells. The administration of the ACLY inhibitor bempedoic acid (BemA) protected against Ang II-induced AAA formation in ApoE mice, limiting the progression of aortic dilatation and reducing mortality due to aortic rupture. BMS-303141, another ACLY inhibitor, also ameliorated AAA formation, although to a lesser extent. BemA attenuated vascular remodeling and the disorganization and rupture of elastic fibers induced by Ang II, as well as vascular inflammation, decreasing the recruitment of macrophages (CD68 +) and neutrophils (Ly-6G+) into the aortic wall. Moreover, BemA shifted splenic monocytes toward a functionally anti-inflammatory phenotype, and increased the percentage of CD4CD69 cells. Taken together, these results support the contribution of ACLY to AAA and point to BemA as a promising tool to be considered for future clinical trials addressing the management of this disease which is quite often associated with disorders of lipoprotein metabolism.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CD69 expression on regulatory T cells protects from immune damage after myocardial infarction

  • Blanco-Domínguez, Rafael
  • Fuente, Hortensia de la
  • Rodríguez-Sinovas, Cristina
  • Martín-Aguado, Laura
  • Sánchez-Díaz, Raquel
  • Jiménez-Alejandre, Rosa
  • Rodríguez-Arabaolaza, Iker
  • Curtabbi, Andrea
  • García-Guimaraes, Marcos M.
  • Vera, Alberto
  • Rivero, Fernando
  • Cuesta, Javier
  • Jiménez-Borreguero, Luis J.
  • Cecconi, Alberto
  • Duran-Cambra, Albert
  • Tauron, Manel
  • Alonso, Judith
  • Bueno, Héctor
  • Villalba-Orero, María
  • Enríquez, Jose Antonio
  • Robson, Simon C.
  • Alfonso, Fernando
  • Sánchez-Madrid, Francisco
  • Martínez-González, José
  • Martín, Pilar
Increasing evidence has pointed to the important function of T cells in controlling immune homeostasis and pathogenesis after myocardial infarction (MI), although the underlying molecular mechanisms remain elusive. In this study, a broad analysis of immune markers in 283 patients revealed significant CD69 overexpression on Tregs after MI. Our results in mice showed that CD69 expression on Tregs increased survival after left anterior descending (LAD) coronary artery ligation. Cd69 mice developed strong IL-17 γδT cell responses after ischemia that increased myocardial inflammation and, consequently, worsened cardiac function. CD69 Tregs, by induction of AhR-dependent CD39 ectonucleotidase activity, induced apoptosis and decreased IL-17A production in γδT cells. Adoptive transfer of CD69 Tregs into Cd69 mice after LAD ligation reduced IL-17 γδT cell recruitment, thus increasing survival. Consistently, clinical data from 2 independent cohorts of patients indicated that increased CD69 expression in peripheral blood cells after acute MI was associated with a lower risk of rehospitalization for heart failure (HF) after 2.5 years of follow-up. This result remained significant after adjustment for age, sex, and traditional cardiac damage biomarkers. Our data highlight CD69 expression on Tregs as a potential prognostic factor and a therapeutic option to prevent HF after MI., This study was supported by competitive grants from the Ministerio de Ciencia e Innovación (MCIN), through the Carlos III Institute of Health (ISCIII) – Fondo de Investigación Sanitaria (PI22/01759), to PM; grant PID2021-122509OB-I00 funded by MCIN/ AEI/10.13039/501100011033 and by “ERDF A way of making Europe” to JMG; Comunidad de Madrid grants S2017/BMD-3671-INFLAMUNE-CM, to PM and FSM; a grant from the Fundació La Marató TV3 (20152330 31), to JMG and FSM; Ministerio de Ciencia e Innovación (MCIN) grant RTI2018- 099357-B-I00 and a CIBERFES grant (CB16/10/00282); and by a Human Frontier Science Program grant (RGP0016/2018) and a Leducq Transatlantic Networks grant (17CVD04), to JAE. AC is supported by a Marie Skłodowska-Curie grant (agreement no. 713673). RBD is supported by the Formación de Profesorado Universitario (FPU16/02780) program of the Spanish Ministry of Education, Culture, and Sports. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN), and the Pro CNIC Foundation) and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

PDE4 Phosphodiesterases in Cardiovascular Diseases: Key Pathophysiological Players and Potential Therapeutic Targets

  • Puertas-Umbert, Lídia
  • Alonso, Judith
  • Hove-Madsen, Leif
  • Martínez-González, José
  • Rodríguez, Cristina
3′,5′-cyclic adenosine monophosphate (cAMP) is a second messenger critically involved in the control of a myriad of processes with significant implications for vascular and cardiac cell function. The temporal and spatial compartmentalization of cAMP is governed by the activity of phosphodiesterases (PDEs), a superfamily of enzymes responsible for the hydrolysis of cyclic nucleotides. Through the fine-tuning of cAMP signaling, PDE4 enzymes could play an important role in cardiac hypertrophy and arrhythmogenesis, while it decisively influences vascular homeostasis through the control of vascular smooth muscle cell proliferation, migration, differentiation and contraction, as well as regulating endothelial permeability, angiogenesis, monocyte/macrophage activation and cardiomyocyte function. This review summarizes the current knowledge and recent advances in understanding the contribution of the PDE4 subfamily to cardiovascular function and underscores the intricate challenges associated with targeting PDE4 enzymes as a therapeutic strategy for the management of cardiovascular diseases., The authors gratefully appreciate the support provided by Instituto de Salud Carlos III (ISCIII; [grant PI21/01048]) and Spanish Ministerio de Ciencia e Innovación (Grant PID2021-122509OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”). We thank the support provided by Fundación Española de Arteriosclerosis (FEA-2020). L.P-U. was supported by a PFIS fellowship (ISCIII)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lysyl oxidase-dependent extracellular matrix crosslinking modulates calcification in atherosclerosis and aortic valve disease

  • Ballester-Servera, Carme
  • Alonso, Judith
  • Cañes, Laia
  • Vázquez-Sufuentes, Paula
  • Puertas-Umbert, Lídia
  • Fernández-Celis, Amaya
  • Taurón, Manel
  • Rodríguez-Sinovas, Antonio
  • López-Andrés, Natalia
  • Rodríguez-Sinovas, Cristina
  • Martínez-González, José
Extracellular matrix (ECM) is an active player in cardiovascular calcification (CVC), a major public health issue with an unmet need for effective therapies. Lysyl oxidase (LOX) conditions ECM biomechanical properties; thus, we hypothesized that LOX might impact on mineral deposition in calcific aortic valve disease (CAVD) and atherosclerosis. LOX was upregulated in calcified valves from two cohorts of CAVD patients. Strong LOX immunostaining was detected surrounding calcified foci in calcified human valves and atherosclerotic lesions colocalizing with RUNX2 on valvular interstitial cells (VICs) or vascular smooth muscle cells (VSMCs). Both LOX secretion and organized collagen deposition were enhanced in calcifying VICs exposed to osteogenic media. β-aminopropionitrile (BAPN), an inhibitor of LOX, attenuated collagen deposition and calcification. VICs seeded onto decellularized matrices from BAPN-treated VICs calcified less than cells cultured onto control scaffolds; instead, VICs exposed to conditioned media from cells over-expressing LOX or cultured onto LOX-crosslinked matrices calcified more. Atherosclerosis was induced in WT and transgenic mice that overexpress LOX in VSMC (TgLOXVSMC) by AAV-PCSK9D374Y injection and high-fat feeding. In atherosclerosis-challenged TgLOXVSMC mice both atherosclerosis burden and calcification assessed by near-infrared fluorescence (NIRF) imaging were higher than in WT mice. These animals also exhibited larger calcified areas in atherosclerotic lesions from aortic arches and brachiocephalic arteries. Moreover, LOX transgenesis exacerbated plaque inflammation, and increased VSMC cellularity, the rate of RUNX2-positive cells and both connective tissue content and collagen cross-linking. Our findings highlight the relevance of LOX in CVC and postulate this enzyme as a potential therapeutic target for CVC., This work was supported by the Spanish Ministerio de Ciencia e Innovación (RTI2018-094727-B-100 and PID2021-122509OB-I00 funded by MCIN/ AEI/10.13039/501100011033 and by “ERDF A way of making Europe”), Instituto de Salud Carlos III (ISCIII; Spain; PI21/01048), and Fundación Española de Arteriosclerosis (FEA-2022). C.B-S and L.P-U were supported by a FPU (Ministerio de Universidades; Spain), and PFIS (ISCIII) fellowships, respectively and N.L-A by a Miguel Servet contract (ISCIII). There is no financial or personal relationship with organizations that could potentially influence the described research., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel pharmacological approaches in abdominal aortic aneurysm

  • Puertas-Umbert, Lídia
  • Almendra-Pegueros, Rafael
  • Jiménez-Altayó, Francesc
  • Sirvent, Marc
  • Galán, María
  • Martínez-González, José
  • Rodríguez-Sinovas, Cristina
Abdominal aortic aneurysm (AAA) is a severe vascular disease and a major public health issue with an unmet medical need for therapy. This disease is featured by a progressive dilation of the abdominal aorta, boosted by atherosclerosis, ageing, and smoking as major risk factors. Aneurysm growth increases the risk of aortic rupture, a life-threatening emergency with high mortality rates. Despite the increasing progress in our knowledge about the etiopathology of AAA, an effective pharmacological treatment against this disorder remains elusive and surgical repair is still the unique available therapeutic approach for high-risk patients. Meanwhile, there is no medical alternative for patients with small aneurysms but close surveillance. Clinical trials assessing the efficacy of antihypertensive agents, statins, doxycycline, or anti-platelet drugs, among others, failed to demonstrate a clear benefit limiting AAA growth, while data from ongoing clinical trials addressing the benefit of metformin on aneurysm progression are eagerly awaited. Recent preclinical studies have postulated new therapeutic targets and pharmacological strategies paving the way for the implementation of future clinical studies exploring these novel therapeutic strategies. This review summarises some of the most relevant clinical and preclinical studies in search of new therapeutic approaches for AAA., This research was funded by the Spanish Ministerio de Ciencia e Innovación (PID2021-122509OB-I00) [grant number MCIN/ AEI/10.13039/501100011033]; “ERDF A way of making Europe”; Instituto de Salud Carlos III (ISCIII) [grants numbers PI21/01048 and PI20/01649]; Fundación Española de Arteriosclerosis-Sociedad Española de Arteriosclerosis (Beca de Investigación Básica 2020); and Fondo Europeo de Desarrollo Regional (FEDER), a way to make Europe. L.P-U. and R.A.-P are supported by a PFIS fellowship (ISCIII)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lysyl Oxidase in Ectopic Cardiovascular Calcification: Role of Oxidative Stress

  • Ballester-Servera, Carme
  • Alonso, Judith
  • Cañes, Laia
  • Vázquez-Sufuentes, Paula
  • García-Redondo, Ana B.
  • Rodríguez, Cristina
  • Martínez-González, José
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Lysyl oxidase (LOX)-mediated extracellular matrix crosslinking modulates calcification in atherosclerosis and aortic valve disease; however, this enzyme also induces oxidative stress. We addressed the contribution of LOX-dependent oxidative stress to cardiovascular calcification. LOX is upregulated in human-calcified atherosclerotic lesions and atheromas from atherosclerosis-challenged LOX transgenic mice (TgLOXVSMC) and colocalized with a marker of oxidative stress (8-oxo-deoxyguanosine) in vascular smooth muscle cells (VSMCs). Similarly, in calcific aortic valves, high LOX expression was detected in valvular interstitial cells (VICs) positive for 8-oxo-deoxyguanosine, while LOX and LOXL2 expression correlated with osteogenic markers (SPP1 and RUNX2) and NOX2. In human VICs, mito-TEMPO and TEMPOL attenuated the increase in superoxide anion levels and the mineralization induced by osteogenic media (OM). Likewise, in OM-exposed VICs, β-aminopropionitrile (a LOX inhibitor) ameliorated both oxidative stress and calcification. Gain- and loss-of-function approaches in VICs demonstrated that while LOX silencing negatively modulates oxidative stress and calcification induced by OM, lentiviral LOX overexpression exacerbated oxidative stress and VIC calcification, effects that were prevented by mito-TEMPO, TEMPOL, and β-aminopropionitrile. Our data indicate that LOX-induced oxidative stress participates in the procalcifying effects of LOX activity in ectopic cardiovascular calcification, and highlight the multifaceted role played by LOX isoenzymes in cardiovascular diseases., This work was supported by the Spanish Ministerio de Ciencia e Innovación (RTI2018-094727-B-100 and PID2021-122509OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”), and Instituto de Salud Carlos III (ISCIII; Spain; PI21/01048). C.B-S was supported by a FPU fellowship (FPU19/05257; Ministerio de Universidades; Spain) and P.V.-S by a FPI fellowhip (PRE2022-103796; Ministerio de Ciencia e Innovación; Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Rolipram impacts on redox homeostasis and cellular signaling in an experimental model of abdominal aortic aneurysm, Impacto del tratamiento con rolipram sobre la homeostasis rédox y la señalización celular en un modelo experimental de aneurisma de aorta abdominal

  • Puertas-Umbert, Lídia
  • Alonso, Judith
  • Roselló-Díez, Elena
  • Santamaría-Orleans, Alicia
  • Martínez-González, José
  • Rodríguez, Cristina
[EN] Cyclic nucleotide phosphodiesterases (PDEs) of the PDE4 subfamily are responsible for the hydrolysis and subcellular compartmentalization of cAMP, a second messenger that modulates vascular functionality. We had shown that PDE4B is induced in abdominal aortic aneurysms (AAA) and that PDE4 inhibition by rolipram limits experimental aneurysms. In this study we have delved into the mechanisms underlying the beneficial effect of rolipram on AAA., [ES] Las fosfodiesterasas de nucleótidos cíclicos (PDEs) de la subfamilia 4 (PDE4) son responsables de la hidrólisis y compartimentalización subcelular del adenosín monofosfato cíclico (AMPc), segundo mensajero que modula la funcionalidad vascular. Habíamos demostrado que la isoforma B de la PDE4 (PDE4B) se induce en el aneurisma de aorta abdominal (AAA) y que la inhibición de la actividad PDE4 mediante rolipram limita la formación de aneurismas experimentales. En este estudio hemos profundizado en los mecanismos que subyacen al efecto beneficioso del rolipram sobre el AAA., Este trabajo ha sido realizado gracias a la financiación obtenida a través de la Fundación Española de Arteriosclerosis (Beca FEA 2020-Investigación Básica III). Además, el estudio ha contado con financiación del Instituto de Salud Carlos III (ISCIII; PI21/01048) y el Ministerio de Ciencia e Innovación (PID2021-122509OB-I00 financiado por MCIN/ AEI/10.13039/501100011033 y por «FEDER Una manera de hacer Europa». L.P-U fue financiada a través de un contrato PFIS (ISCIII)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Upregulation of NOR-1 in calcified human vascular tissues: impact on osteogenic differentiation and calcification

  • Ballester-Servera, Carme
  • Cañes, Laia
  • Alonso, Judith
  • Puertas-Umbert, Lídia
  • Vázquez-Sufuentes, Paula
  • Taurón, Manel
  • Roselló-Díez, Elena
  • Marin, Francisco R.
  • Rodríguez, Cristina
  • Martínez-González, José
Cardiovascular calcification is a significant public health issue whose pathophysiology is not fully understood. NOR-1 regulates critical processes in cardiovascular remodeling, but its contribution to ectopic calcification is unknown. NOR-1 was overexpressed in human calcific aortic valves and calcified atherosclerotic lesions colocalizing with RUNX2, a factor essential for osteochondrogenic differentiation and calcification. NOR-1 and osteogenic markers were upregulated in calcifying human valvular interstitial cells (VICs) and human vascular smooth muscle cells (VSMCs). Gain- and loss-of-function approaches demonstrated that NOR-1 negatively modulates the expression of osteogenic genes relevant for the osteogenic transdifferentiation (RUNX2, IL-6, BMP2, and ALPL) and calcification of VICs. VSMCs from transgenic mice overexpressing NOR-1 in these cells (TgNOR-1VSMC) expressed lower basal levels of osteogenic genes (IL-6, BMP2, ALPL, OPN) than cells from WT littermates, and their upregulation by a high-phosphate osteogenic medium (OM) was completely prevented by NOR-1 transgenesis. Consistently, this was associated with a dramatic reduction in the calcification of both transgenic VSMCs and aortic rings from TgNOR-1VSMC mice exposed to OM. Atherosclerosis and calcification were induce in mice by the administration of AAV-PCSK9D374Y and a high-fat/high-cholesterol diet. Challenged-TgNOR-1VSMC mice exhibited decreased vascular expression of osteogenic markers, and both less atherosclerotic burden (assessed in whole aorta and lesion size in aortic arch and brachiocephalic artery) and less vascular calcification (assessed either by near-infrared fluorescence imaging or histological analysis) than WT mice. Our data indicate that NOR-1 negatively modulates the expression of genes critically involved in the osteogenic differentiation of VICs and VSMCs, thereby restraining ectopic cardiovascular calcification., This work was supported by the Spanish Ministerio de Ciencia e Innovación ( RTI2018-094727-B-100 and PID2021-122509OB-I00 funded by MCIN/ AEI/10.13039/501100011033 and by “ERDF A way of making Europe”), Instituto de Salud Carlos III (ISCIII; Spain) ( PI21/01048 ), and Sociedad Española de Arteriosclerosis ( SEA-2022 ). C.B-S and L.P-U were supported by a FPU (Ministerio de Universidades; Spain), and PFIS fellowships, respectively., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NADPH Oxidase 5 (NOX5) Upregulates MMP-10 Production and Cell Migration in Human Endothelial Cells

  • Marqués, Javier
  • Ainzúa, Elena
  • Orbe, Josune
  • Martínez-Azcona, María
  • Martínez-González, José
  • Zalba, Guillermo
NADPH oxidases (NOXs) have been described as critical players in vascular remodeling, a mechanism modulated by matrix metalloproteinases. In this study, we describe for the first time the upregulation of MMP-10 through the activation of NOX5 in endothelial cells. In a chronic NOX5 overexpression model in human endothelial cells, MMP-10 production was measured at different levels: extracellular secretion, gene expression (mRNA and protein levels), and promoter activity. Effects on cell migration were quantified using wound healing assays. NOX5 overexpression increased MMP-10 production, favoring cell migration. In fact, NOX5 and MMP-10 silencing prevented this promigratory effect. We showed that NOX5-mediated MMP-10 upregulation involves the redox-sensitive JNK/AP-1 signaling pathway. All these NOX5-dependent effects were enhanced by angiotensin II (Ang II). Interestingly, MMP-10 protein levels were found to be increased in the hearts of NOX5-expressing mice. In conclusion, we described that NOX5-generated ROS may modulate the MMP-10 expression in endothelial cells, which leads to endothelial cell migration and may play a key role in vascular remodeling., This work was supported by the departments of Health (40/2021) University, Innovation and Digital Transformation (Proyectos I + D colaborativos 2020-PC159/160/161, NOXICTUS) from the Government of Navarra, by the Spanish Ministry of Science and Innovation (Instituto de Salud Carlos III-Fondo de Investigaciones Sanitarias, PI22/01450; PID2021-122509OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”). E.A. and J.M. were supported by an FPU PhD Grant from the Spanish Ministry of Universities (FPU21/03340 and FPU19/01807, respectively)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Análisis de vías y genes implicados en la dilatación temprana del aneurisma de aorta abdominal en el modelo de animal transgénico de NOR-1

  • Vázquez-Sufuentes, Paula
  • Ballester-Servera, Carme
  • Martín Fernández, L.
  • Comes, N.
  • Alonso, Judith
  • Borrás, Nina
  • Corrales, Irene
  • Vidal, Francisco
  • Rodríguez-Sinovas, Cristina
  • Martínez-González, José
Trabajo presentado en el XXXVI Congreso de la Sociedad Española de Arteriosclerosis, celebrado en Castellón (España) del 12 al 14 de junio de 2024, Introducción: El aneurisma de aorta abdominal (AAA) es una enfermedad con una elevada morbimortalidad, caracterizada por la progresiva dilatación de la aorta que puede culminar en su rotura. El receptor nuclear NOR-1 participa en el desarrollo del AAA, tanto en pacientes como en modelos experimentales. Objetivo: Identificar genes regulados por NOR-1 implicados en AAA. Materiales y métodos: Se implantaron minibombas de infusión de angiotensina II (1000 ng/kg/min) a ratones transgénicos que sobreexpresan NOR-1 en células musculares lisas vasculares (TgNOR-1VSMC) y a controles, y se analizó el diámetro de la aorta mediante ecografía (VisualSonics Vevo 2100). Se extrajo RNA de las aortas de los animales que experimentaron dilatación temprana (incremento 25-40% en 4-7 días). Se determinaron los cambios en el transcriptoma mediante secuenciación del RNA (Illumina Stranded mRNA Prep) y se analizaron las vías enriquecidas (GSEA y ORA) usando la base de datos Gene Ontology mediante la herramienta WebGestalt. Los genes más relevantes se validaron por PCR, se clonaron sus promotores y se estudió su regulación mediante la transfección transitoria de construcciones reporteras de luciferasa. Resultados. La secuenciación de RNA mostró una expresión diferencial significativa de 334 genes de los cuales 145 presentaron un Fold-Change >1,5. El análisis bioinformático de vías enriquecidas destacó dos poblaciones funcionales bien diferenciadas: genes de vías inflamatorias y genes implicados en contracción/diferenciación muscular. Mediante PCR a tiempo real se confirmó la inducción de dichos genes y, mediante el análisis de la actividad transcripcional con construcciones de la región promotora proximal, la implicación de NOR-1 en su regulación. Conclusiones. NOR-1 regula la expresión de genes implicados en inflamación y en la transformación fenotípica que experimentan las CMLVs en las primeras fases de la dilatación aórtica que conduce a la formación del AAA., Proyectos PID2021-122509OB-I00 financiado por MCIN/AEI/10.13039/501100011033, FEDER Una manera de hacer Europa y por ISCIII (PI21/01048).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

La expresión de la lisil oxidasa en las células musculares lisas determina el nivel de calcificación de la íntima en la aterosclerosis inducida por hipercolesterolemia, Lysyl oxidase expression in smooth muscle cells determines the level of intima calcification in hypercholesterolemia-induced atherosclerosis

  • Ballester-Servera, Carme
  • Alonso, Judith
  • Taurón, Manel
  • Rotllan, Noemi
  • Rodríguez, Cristina
  • Martínez-González, José
[EN] Introduction Cardiovascular calcification is an important public health issue with an unmeet therapeutic need. We had previously shown that lysyl oxidase (LOX) activity critically influences vascular wall smooth muscle cells (VSMCs) and valvular interstitial cells (VICs) calcification by affecting extracellular matrix remodeling. We have delved into the participation of LOX in atherosclerosis and vascular calcification, as well as in the mineralization of the aortic valve. Methods Immunohistochemical and expression studies were carried out in human atherosclerotic lesions and experimental models, valves from patients with aortic stenosis, VICs, and in a genetically modified mouse model that overexpresses LOX in CMLV (TgLOXCMLV). Hyperlipemia and atherosclerosis was induced in mice through the administration of adeno-associated viruses encoding a PCSK9 mutated form (AAV-PCSK9D374Y) combined with an atherogenic diet. Results LOX expression is increased in the neointimal layer of atherosclerotic lesions from human coronary arteries and in VSMC-rich regions of atheromas developed both in the brachiocephalic artery of control (C57BL/6J) animals transduced with PCSK9D374Y and in the aortic root of ApoE−/− mice. In TgLOXCMLV mice, PCSK9D374Y transduction did not significantly alter the enhanced aortic expression of genes involved in matrix remodeling, inflammation, oxidative stress and osteoblastic differentiation. Likewise, LOX transgenesis did not alter the size or lipid content of atherosclerotic lesions in the aortic arch, brachiocephalic artery and aortic root, but exacerbated calcification. Among lysyl oxidase isoenzymes, LOX is the most expressed member of this family in highly calcified human valves, colocalizing with RUNX2 in VICs. The lower calcium deposition and decreased RUNX2 levels triggered by the overexpression of the nuclear receptor NOR-1 in VICs was associated with a reduction in LOX. Conclusions Our results show that LOX expression is increased in atherosclerotic lesions, and that overexpression of this enzyme in VSMC does not affect the size of the atheroma or its lipid content, but it does affect its degree of calcification. Further, these data suggest that the decrease in calcification driven by NOR-1 in VICs would involve a reduction in LOX. These evidences support the interest of LOX as a therapeutic target in cardiovascular calcification., [ES] Introducción La calcificación cardiovascular es un importante problema de salud pública para el que no se dispone de estrategias farmacológicas eficaces. Previamente habíamos demostrado que la actividad lisil oxidasa (LOX) influye de manera determinante en la calcificación de las células musculares lisas de la pared vascular (CMLV) y las células intersticiales valvulares (VIC) a través de su impacto en el remodelado de la matriz extracelular. Hemos profundizado en la participación de la LOX en la aterosclerosis y la calcificación asociada, así como en la mineralización de la válvula aórtica. Métodos Se realizaron análisis inmunohistoquímicos y de expresión en lesiones ateroscleróticas humanas y de modelos experimentales, válvulas de pacientes con estenosis aórtica, VIC y estudios en un modelo de ratón modificado genéticamente que sobreexpresa LOX en CMLV (TgLOXCMLV), en el que se indujo hiperlipemia y aterosclerosis mediante la administración de virus adenoasociados que codifican para una forma mutada de la PCSK9 (AAV-PCSK9D374Y) y dieta aterogénica. Resultados La expresión de la LOX se incrementa en la neoíntima de lesiones ateroscleróticas de arterias coronarias humanas y en regiones ricas en CMLV de las placas de ateroma desarrolladas tanto en la arteria braquiocefálica de animales control (C57BL/6J) transducidos con PCSK9D374Y como en la raíz aórtica de ratones ApoE−/−. En ratones TgLOXCMLV, la transducción con PCSK9D374Y no alteró significativamente el incremento de la expresión aórtica de genes implicados en el remodelado de la matriz, la inflamación, el estrés oxidativo y la diferenciación osteoblástica. La transgénesis de LOX no afectó al tamaño ni al contenido lipídico de las lesiones ateroscleróticas del arco aórtico, la arteria braquiocefálica y la raíz aórtica, pero exacerbó la calcificación de la íntima de las lesiones. Entre las isoenzimas de la familia de lisil oxidasas, la LOX es el miembro más expresado en válvulas de pacientes muy calcificadas, detectándose en células VIC positivas para RUNX2. La menor deposición de calcio y la disminución de RUNX2 causadas por la sobreexpresión del receptor nuclear NOR-1 en VIC se asoció a una reducción de los niveles de proteína de LOX. Conclusiones Nuestros resultados muestran que la expresión de LOX está aumentada en lesiones ateroscleróticas, y que la sobreexpresión de esta enzima en CMLV no afecta al tamaño ni al contenido lipídico de las lesiones pero sí a su grado de calcificación. Además, sugieren que la disminución de la calcificación inducida por NOR-1 en VIC estaría mediada por una reducción en nivel de LOX. Estas evidencias apoyan el interés de la LOX como diana terapéutica en la calcificación cardiovascular., Este trabajo ha sido realizado gracias a la financiación obtenida a través de la Fundación Española de Arteriosclerosis (Beca FEA 2022 Investigación Básica en Arteriosclerosis). Además, el estudio ha contado con financiación del Instituto de Salud Carlos III (PI21/01048) y del Ministerio de Ciencia e Innovación (PID2021-122509OB-I00 financiado por MCIN/ AEI/10.13039/501100011033 y por “FEDER Una manera de hacer Europa”. C.B.-S está financiada a través de un contrato FPU (FPU19/05257, Ministerio de Universidades)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Papel del estrés oxidativo derivado de la actividad LOX en la calcificación cardiovascular

  • Ballester-Servera, Carme
  • Alonso, Judith
  • Cañes, Laia
  • Vázquez-Sufuentes, Paula
  • García-Redondo, Ana B.
  • Rodríguez, Cristina
  • Martínez-González, José
Trabajo presentado en el XXXVI Congreso de la Sociedad Española de Arteriosclerosis, celebrado en Castellón (España) del 12 al 14 de junio de 2024, Introducción: El remodelado de la matriz extracelular (MEX) y el estrés oxidativo juegan un papel importante en la calcificación cardiovascular. La lisil oxidasa (LOX), enzima que participa en la maduración de la MEX y contribuye al estrés oxidativo, se ha implicado en la calcificación de las células musculares lisas vasculares (CMLVs). Objetivo: Analizar la contribución de las especies reactivas de oxigeno (ROS) derivadas de la actividad LOX en la calcificación cardiovascular. Materiales y métodos: Se utilizaron arterias humanas con lesión aterosclerótica y válvulas aórticas calcificadas. Se realizaron estrategias de ganancia o pérdida de función LOX en células intersticiales valvulares (VICs) expuestas a medio osteogénico (OM). Se indujo aterosclerosis en ratones transgénicos que sobreexpresan LOX en CMLVs (TgLOXCMLV) administrando virus adenoasociados AAV-PCSK9D374Y y dieta aterogénica. Resultados: LOX está aumentada tanto en lesiones ateroscleróticas humanas calcificadas como en placas ateroscleróticas de ratones TgLOXCMLV y colocaliza con un marcador de estrés oxidativo (8-oxo-deoxiguanosina) en CMLVs positivas para RUNX2. Asimismo, válvulas aórticas humanas calcificadas mostraron una mayor expresión de LOX en VICs positivas para 8-oxo-deoxiguanosina y RUNX2. La expresión de LOX y LOXL2 correlacionó positivamente con marcadores osteogénicos (RUNX2 y SPP1) y NOX2. VICs expuestas a OM mostraron mayores niveles de ROS y mayor mineralización de la MEX, efectos que fueron atenuados por los antioxidantes mito-TEMPO y TEMPOL y por BAPN (inhibidor de la actividad LOX). El silenciamiento de LOX en VICs moduló negativamente el estrés oxidativo y la mineralización de la MEX mientras que la sobreexpresión de LOX exacerbó los niveles de ROS y la calcificación, efectos que fueron prevenidos por mito-TEMPO, TEMPOL y BAPN. Conclusión: El estrés oxidativo derivado de la actividad LOX contribuye al efecto potenciador de la calcificación cardiovascular ectópica asociado a esta enzima., Proyectos PID2021-122509OB-I00 financiado por MCIN/AEI/10.13039/501100011033 y FEDER Una manera de hacer Europa y PI21/01048-ISCIII
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Inhibition of ATP-citrate lyase by bempedoic acid protects against abdominal aortic aneurysm formation in mice

  • Puertas-Umbert, Lídia
  • Alonso, Judith
  • Blanco-Casoliva, Laia
  • Almendra-Pegueros, Rafael
  • Camacho, Mercedes
  • Rodríguez-Sinovas, Antonio
  • Galán, María
  • Roglans, Nuria
  • Laguna, Juan Carlos
  • Martínez-González, José
  • Rodríguez, Cristina
Abdominal aortic aneurysm (AAA) is a prevalent degenerative disease characterized by an exacerbated inflammation and destructive vascular remodeling. Unfortunately, effective pharmacological tools for the treatment of this disease remain a challenge. ATP-citrate lyase (ACLY), the primary enzyme responsible for acetyl-CoA biosynthesis, is a key regulator of inflammatory signaling in macrophages and lymphocytes. Here, we found increased levels of the active (phosphorylated) form of ACLY (p-ACLY) in the inflammatory infiltrate of AAA from patients and in aneurysmal lesions from angiotensin II (Ang II)-infused apolipoprotein E-deficient mice (ApoE-/-). Furthermore, plasma ACLY levels positively correlates with IL6 and IFNγ levels in patients with AAA, while inflammatory stimuli strongly upregulated ACLY expression in macrophages and Jurkat cells. The administration of the ACLY inhibitor bempedoic acid (BemA) protected against Ang II-induced AAA formation in ApoE-/- mice, limiting the progression of aortic dilatation and reducing mortality due to aortic rupture. BMS-303141, another ACLY inhibitor, also ameliorated AAA formation, although to a lesser extent. BemA attenuated vascular remodeling and the disorganization and rupture of elastic fibers induced by Ang II, as well as vascular inflammation, decreasing the recruitment of macrophages (CD68 +) and neutrophils (Ly-6G+) into the aortic wall. Moreover, BemA shifted splenic monocytes toward a functionally anti-inflammatory phenotype, and increased the percentage of CD4+CD69+ cells. Taken together, these results support the contribution of ACLY to AAA and point to BemA as a promising tool to be considered for future clinical trials addressing the management of this disease which is quite often associated with disorders of lipoprotein metabolism., This work was supported by the Instituto de Salud Carlos III (ISCIII; [grants PI21/01048 and PI24/00613]), Fundación Eugenio Rodríguez Pascual (call 2022) and the Spanish Ministerio de Ciencia e Innovación (Grants PID2021-122509OB-I00 and PID2023-146140OB-100 funded by MCIN/AEI/10.13039/501100011033, and by “ERDF A way of making Europe”). We thank the support provided by Fundación Española de Arteriosclerosis (FEA-2024-Investigación Básica en Arteriosclerosis), Fundación Española de Cardiología (SEC/FEC-INV-BAS 24/03) AGAUR (2021SGR-00345 and 2021SGR-00826) and Fundació La Marató de TV3 (202325-30-31). L.P-U and R.A.P. were supported by PFIS (ISCIII) fellowships (FI19/00331 and FI21/00125, respectively)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

La inhibición de ATP-citrato liasa por el ácido bempedoico protege contra el aneurisma de aorta abdominal

  • Blanco-Casoliva, Laia
  • Puertas-Umbert, Lídia
  • Alonso, Judith
  • Almendra-Pegueros, Rafael
  • Camacho, Mercedes
  • Rodríguez-Sinovas, Antonio
  • Galán, María
  • Roglans, Nuria
  • Laguna, Juan Carlos
  • Martínez-González, José
  • Rodríguez, Cristina
Trabajo presentado en el XXXVII Congreso de la Sociedad Española de Arteriosclerosis, celebrado en Sitges, Barcelona, del 4 al 6 de junio de 2025, Objetivo El aneurisma de aorta abdominal (AAA) es una enfermedad degenerativa, caracterizada por una exacerbada inflamación y un remodelado destructivo de la pared vascular, para la que no se dispone de tratamiento farmacológico. La ATP-citrato liasa (ACLY) es la principal enzima responsable de la biosíntesis del acetil-CoA y regula la señalización inflamatoria. Sin embargo, se desconoce su posible contribución al AAA. Métodos Los estudios se realizaron en muestras de aorta abdominal de pacientes con AAA y donantes sanos y en un modelo experimental de AAA (ratones deficientes en apolipoproteina E (ApoE-/-) infundidos con angiotensina II (AngII)), que se trató con ácido bempedoico (BemA), inhibidor de la ACLY. Resultados La forma activa (fosforilada) de la ACLY aumenta en lesiones aneurismáticas humanas y murinas en las que se localiza en el infiltrado inflamatorio. Además, en pacientes con AAA, los niveles plasmáticos de ACLY correlacionan positivamente con los de IL6 e IFN. A su vez, la expresión de ACLY se incrementó en macrófagos y células Jurkat en respuesta a estímulos inflamatorios. En el modelo experimental, el BemA protegió frente a la formación de AAA, reduciendo la dilatación aórtica y la mortalidad por rotura vascular. Análogamente, el BMS-303141, otro inhibidor de esta enzima, también atenuó la formación de AAA, aunque en menor medida. El BemA limitó el remodelado vascular, la desorganización y rotura de las fibras elásticas, así como la inflamación vascular, disminuyendo el reclutamiento de macrófagos (CD68+), linfocitos (CD3+) y neutrófilos (Ly-6G+). Además, este fármaco promovió la transformación de los monocitos esplénicos hacia un fenotipo antiinflamatorio. Conclusiones Estos resultados apoyan la contribución de la ACLY al AAA y sugieren que el BemA podría constituir una herramienta de interés en futuros ensayos clínicos que aborden el manejo de esta enfermedad., Financiado por FEA2024(I), PI24/00613 y PID2021-122509OB-I00, MCIN/AEI/10.13039/501100011033 y “ERDF A way of making Europe”, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Perivascular adipose tissue modulates aortic reactivity in Marfan syndrome mice in a sex- and region-specific manner: Redox-dependent anticontractile effects in the female ascending aorta

  • Hua-Monclús, Jana
  • Penas, Clara
  • Pérez, Belén
  • Almendra-Pegueros, Rafael
  • Galán, María
  • García-Aranda, Julián
  • Kreuzer, Martin
  • Manich, Gemma
  • Rodríguez-Sinovas, Cristina
  • Martínez-González, José
  • Davel, Ana P.
  • Jiménez-Altayó, Francesc
Marfan syndrome (MFS), caused by fibrillin-1 (FBN1) mutations, leads to thoracic aortic aneurysm formation through mechanisms in which redox imbalance plays an important role. Perivascular adipose tissue (PVAT) modulates vascular tone, but its role in aortic reactivity in MFS is unknown. To address this, we examined thoracic aortic reactivity using wire myography in ascending and descending aortic segments from 2 to 3-month-old male and female wild-type and Fbn1C1041G/+ mice with or without PVAT. PVAT-mediated modulation of α1-adrenergic phenylephrine-induced contractions was preserved in the ascending aorta of male MFS mice. In contrast, in the descending thoracic aorta, PVAT from MFS mice exerted an anticontractile effect irrespective of sex. In the female ascending aorta, PVAT induced a genotype-dependent attenuation of contractile responses that persisted after endothelial denudation but was lost with aging. Despite comparable nitric oxide synthase (NOS) expression and NO levels, pharmacological NOS inhibition with L-NAME or selective inducible NOS blockade with 1400 W abolished the PVAT-induced anticontractile effect. Molecular, histological, and synchrotron radiation-based Fourier-transform infrared microspectroscopy analyses showed increased Nox4 expression and oxidative-nitrosative stress in MFS PVAT, without evidence of lipid oxidation or changes in protein secondary structure. Catalase (an H2O2 scavenger) or FeTPPS (a peroxynitrite decomposition catalyst) abolished the PVAT-dependent attenuation of contractility, supporting an integrated redox signaling mechanism. These findings identify PVAT as a sex- and region-specific modulator of aortic reactivity in MFS. In female mice, PVAT-dependent attenuation of α1-adrenergic contractility involves redox-sensitive pathways, highlighting PVAT-derived reactive oxygen/nitrogen species signaling as a potential therapeutic target in MFS-associated aortopathy., This work was supported by the Ministerio de Ciencia e Innovación and Agencia Estatal de Investigación of Spain (PID2020-113634RB-C22/AEI/https://doi.org/10.13039/501100011033 to F.J.-A. and PID2021-122509OB-I00/AEI/https://doi.org/10.13039/501100011033 to J.M.-G.); the Instituto de Salud Carlos III (PI24/00613 to C.R.); the Generalitat de Catalunya (2021 SGR 00969 to F.J.-A); and Fundació la Marató de TV3 (202308–30-31–31 to M.G.)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Novel pharmacological approaches in abdominal aortic aneurysm

  • Puertas Umbert, Lídia|||0000-0002-2739-6522
  • Almendra-Pegueros, Rafael|||0000-0002-4411-4515
  • Jiménez Altayó, Francesc|||0000-0002-9034-2041
  • Sirvent, Marc|||0000-0001-5912-8760
  • Galán, María|||0000-0002-4758-8388
  • Martínez-González, José|||0000-0002-3894-7166
  • Rodríguez, Cristina|||0000-0002-6472-5647
Abdominal aortic aneurysm (AAA) is a severe vascular disease and a major public health issue with an unmet medical need for therapy. This disease is featured by a progressive dilation of the abdominal aorta, boosted by atherosclerosis, ageing, and smoking as major risk factors. Aneurysm growth increases the risk of aortic rupture, a life-threatening emergency with high mortality rates. Despite the increasing progress in our knowledge about the etiopathology of AAA, an effective pharmacological treatment against this disorder remains elusive and surgical repair is still the unique available therapeutic approach for high-risk patients. Meanwhile, there is no medical alternative for patients with small aneurysms but close surveillance. Clinical trials assessing the efficacy of antihypertensive agents, statins, doxycycline, or anti-platelet drugs, among others, failed to demonstrate a clear benefit limiting AAA growth, while data from ongoing clinical trials addressing the benefit of metformin on aneurysm progression are eagerly awaited. Recent preclinical studies have postulated new therapeutic targets and pharmacological strategies paving the way for the implementation of future clinical studies exploring these novel therapeutic strategies. This review summarises some of the most relevant clinical and preclinical studies in search of new therapeutic approaches for AAA.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Lysyl Oxidase in Ectopic Cardiovascular Calcification, Role of Oxidative Stress

  • Ballester-Servera, Carme|||0000-0001-7858-3064
  • Alonso Nieto, Judith|||0000-0003-0537-0417
  • Cañes Esteve, Laia|||0000-0002-9579-1321
  • Vázquez-Sufuentes, Paula|||0009-0001-3369-9087
  • Garcia Redondo, Ana B.|||0000-0002-5815-3320
  • Rodríguez, Cristina|||0000-0002-6472-5647
  • Martínez-González, José|||0000-0002-3894-7166
Lysyl oxidase (LOX)-mediated extracellular matrix crosslinking modulates calcification in atherosclerosis and aortic valve disease; however, this enzyme also induces oxidative stress. We addressed the contribution of LOX-dependent oxidative stress to cardiovascular calcification. LOX is upregulated in human-calcified atherosclerotic lesions and atheromas from atherosclerosis-challenged LOX transgenic mice (TgLOX) and colocalized with a marker of oxidative stress (8-oxo-deoxyguanosine) in vascular smooth muscle cells (VSMCs). Similarly, in calcific aortic valves, high LOX expression was detected in valvular interstitial cells (VICs) positive for 8-oxo-deoxyguanosine, while LOX and LOXL2 expression correlated with osteogenic markers (SPP1 and RUNX2) and NOX2. In human VICs, mito-TEMPO and TEMPOL attenuated the increase in superoxide anion levels and the mineralization induced by osteogenic media (OM). Likewise, in OM-exposed VICs, β-aminopropionitrile (a LOX inhibitor) ameliorated both oxidative stress and calcification. Gain- and loss-of-function approaches in VICs demonstrated that while LOX silencing negatively modulates oxidative stress and calcification induced by OM, lentiviral LOX overexpression exacerbated oxidative stress and VIC calcification, effects that were prevented by mito-TEMPO, TEMPOL, and β-aminopropionitrile. Our data indicate that LOX-induced oxidative stress participates in the procalcifying effects of LOX activity in ectopic cardiovascular calcification, and highlight the multifaceted role played by LOX isoenzymes in cardiovascular diseases.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

PDE4 Phosphodiesterases in Cardiovascular Diseases, Key Pathophysiological Players and Potential Therapeutic Targets

  • Puertas Umbert, Lídia|||0000-0002-2739-6522
  • Alonso Nieto, Judith|||0000-0003-0537-0417
  • Madsen, Leif Hove|||0000-0001-5493-3998
  • Martínez-González, José|||0000-0002-3894-7166
  • Rodríguez, Cristina|||0000-0002-6472-5647
3',5'-cyclic adenosine monophosphate (cAMP) is a second messenger critically involved in the control of a myriad of processes with significant implications for vascular and cardiac cell function. The temporal and spatial compartmentalization of cAMP is governed by the activity of phosphodiesterases (PDEs), a superfamily of enzymes responsible for the hydrolysis of cyclic nucleotides. Through the fine-tuning of cAMP signaling, PDE4 enzymes could play an important role in cardiac hypertrophy and arrhythmogenesis, while it decisively influences vascular homeostasis through the control of vascular smooth muscle cell proliferation, migration, differentiation and contraction, as well as regulating endothelial permeability, angiogenesis, monocyte/macrophage activation and cardiomyocyte function. This review summarizes the current knowledge and recent advances in understanding the contribution of the PDE4 subfamily to cardiovascular function and underscores the intricate challenges associated with targeting PDE4 enzymes as a therapeutic strategy for the management of cardiovascular diseases.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Upregulation of NOR-1 in calcified human vascular tissues, impact on osteogenic differentiation and calcification

  • Ballester-Servera, Carme|||0000-0001-7858-3064
  • Cañes Esteve, Laia|||0000-0002-9579-1321
  • Alonso Nieto, Judith|||0000-0003-0537-0417
  • Puertas Umbert, Lídia|||0000-0002-2739-6522
  • Vázquez-Sufuentes, Paula|||0009-0001-3369-9087
  • Tauron, Manel|||0000-0002-5864-519X
  • Roselló-Díez, Elena|||0000-0003-2258-3246
  • Marín, Francisco|||0000-0001-7246-7708
  • Rodríguez, Cristina|||0000-0002-6472-5647
  • Martínez-González, José|||0000-0002-3894-7166
Cardiovascular calcification is a significant public health issue whose pathophysiology is not fully understood. NOR-1 regulates critical processes in cardiovascular remodeling, but its contribution to ectopic calcification is unknown. NOR-1 was overexpressed in human calcific aortic valves and calcified atherosclerotic lesions colocalizing with RUNX2, a factor essential for osteochondrogenic differentiation and calcification. NOR-1 and osteogenic markers were upregulated in calcifying human valvular interstitial cells (VICs) and human vascular smooth muscle cells (VSMCs). Gain- and loss-of-function approaches demonstrated that NOR-1 negatively modulates the expression of osteogenic genes relevant for the osteogenic transdifferentiation (RUNX2, IL-6, BMP2, and ALPL) and calcification of VICs. VSMCs from transgenic mice overexpressing NOR-1 in these cells (TgNOR-1) expressed lower basal levels of osteogenic genes (IL-6, BMP2, ALPL, OPN) than cells from WT littermates, and their upregulation by a high-phosphate osteogenic medium (OM) was completely prevented by NOR-1 transgenesis. Consistently, this was associated with a dramatic reduction in the calcification of both transgenic VSMCs and aortic rings from TgNOR-1 mice exposed to OM. Atherosclerosis and calcification were induce in mice by the administration of AAV-PCSK9 and a high-fat/high-cholesterol diet. Challenged-TgNOR-1 mice exhibited decreased vascular expression of osteogenic markers, and both less atherosclerotic burden (assessed in whole aorta and lesion size in aortic arch and brachiocephalic artery) and less vascular calcification (assessed either by near-infrared fluorescence imaging or histological analysis) than WT mice. Our data indicate that NOR-1 negatively modulates the expression of genes critically involved in the osteogenic differentiation of VICs and VSMCs, thereby restraining ectopic cardiovascular calcification.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Lysyl oxidase-dependent extracellular matrix crosslinking modulates calcification in atherosclerosis and aortic valve disease

  • Ballester-Servera, Carme|||0000-0001-7858-3064
  • Alonso Nieto, Judith|||0000-0003-0537-0417
  • Cañes Esteve, Laia|||0000-0002-9579-1321
  • Vázquez-Sufuentes, Paula|||0009-0001-3369-9087
  • Puertas Umbert, Lídia|||0000-0002-2739-6522
  • Fernández-Celis, A.
  • Tauron, Manel|||0000-0002-5864-519X
  • Rodríguez Sinovas, Antonio|||0000-0003-2930-8773
  • López-Andrés, N.
  • Rodríguez, Cristina|||0000-0002-6472-5647
  • Martínez-González, José|||0000-0002-3894-7166
Extracellular matrix (ECM) is an active player in cardiovascular calcification (CVC), a major public health issue with an unmet need for effective therapies. Lysyl oxidase (LOX) conditions ECM biomechanical properties; thus, we hypothesized that LOX might impact on mineral deposition in calcific aortic valve disease (CAVD) and atherosclerosis. LOX was upregulated in calcified valves from two cohorts of CAVD patients. Strong LOX immunostaining was detected surrounding calcified foci in calcified human valves and atherosclerotic lesions colocalizing with RUNX2 on valvular interstitial cells (VICs) or vascular smooth muscle cells (VSMCs). Both LOX secretion and organized collagen deposition were enhanced in calcifying VICs exposed to osteogenic media. β-aminopropionitrile (BAPN), an inhibitor of LOX, attenuated collagen deposition and calcification. VICs seeded onto decellularized matrices from BAPN-treated VICs calcified less than cells cultured onto control scaffolds; instead, VICs exposed to conditioned media from cells over-expressing LOX or cultured onto LOX-crosslinked matrices calcified more. Atherosclerosis was induced in WT and transgenic mice that overexpress LOX in VSMC (TgLOX) by AAV-PCSK9D374Y injection and high-fat feeding. In atherosclerosis-challenged TgLOX mice both atherosclerosis burden and calcification assessed by near-infrared fluorescence (NIRF) imaging were higher than in WT mice. These animals also exhibited larger calcified areas in atherosclerotic lesions from aortic arches and brachiocephalic arteries. Moreover, LOX transgenesis exacerbated plaque inflammation, and increased VSMC cellularity, the rate of RUNX2-positive cells and both connective tissue content and collagen cross-linking. Our findings highlight the relevance of LOX in CVC and postulate this enzyme as a potential therapeutic target for CVC.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Targeting lysyl-oxidase (LOX) may facilitate intramural periarterial drainage for the treatment of Alzheimer's disease

  • Kelly, Louise|||0000-0002-5119-519X
  • Sharp, Matthew Macgregor|||0000-0002-6623-5078
  • Thomas, Isabelle
  • Brown, Christopher
  • Schrag, Matthew
  • Antunes, Lissa Ventura
  • Solopova, Elena|||0000-0001-5508-0368
  • Martínez-González, José Pablo|||0000-0002-5925-1010
  • Rodríguez, Cristina|||0000-0002-6472-5647
  • Carare, Roxana Octavia
Alzheimer's disease is the commonest form of dementia. It is likely that a lack of clearance of amyloid beta (Aβ) results in its accumulation in the parenchyma as Aβ oligomers and insoluble plaques, and within the walls of blood vessels as cerebral amyloid angiopathy (CAA). The drainage of Aβ along the basement membranes of blood vessels as intramural periarterial drainage (IPAD), could be improved if the driving force behind IPAD could be augmented, therefore reducing Aβ accumulation. There are alterations in the composition of the vascular basement membrane in Alzheimer's disease. Lysyl oxidase (LOX) is an enzyme involved in the remodelling of the extracellular matrix and its expression and function is altered in various disease states. The expression of LOX is increased in Alzheimer's disease, but it is unclear whether this is a contributory factor in the impairment of IPAD in Alzheimer's disease. The pharmacological inhibition of LOX may be a strategy to improve IPAD and reduce the accumulation of Aβ in the parenchyma and within the walls of blood vessels.